Wealthspire Advisors LLC Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Wealthspire Advisors LLC trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,979 shares of the company’s stock after selling 1,358 shares during the period. Wealthspire Advisors LLC’s holdings in IDEXX Laboratories were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $31,000. Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $37,000. Finally, Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $38,000. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock valued at $6,161,276 in the last three months. Company insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IDXX. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Trading Up 2.4 %

NASDAQ IDXX opened at $463.66 on Tuesday. The stock has a market cap of $37.97 billion, a PE ratio of 43.45, a PEG ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company’s 50-day moving average price is $432.58 and its 200-day moving average price is $452.04. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.